Three papers published today show that aspirin, taken daily, may prevent cancer, and could even treat certain cancers.
Endocrine-therapy resistant HER2-negative breast cancer is the most common cause of breast cancer death. The basis for this resistance is heavily studied to identify new ways to treat these patients.
Reasons for recurrence after treatment for early breast cancer are still not well understood. Lifestyle and other longer-term factors are likely at play, but the subject is difficult to study. The best advice for cancer patients is exercise and a healthy diet.
Typically women who are likely to be treated with systemic therapy before surgery have bulky disease. But should all breast cancer patients receive systemic neoadjuvant therapy?
Over the past several months, the results of four randomized bisphosphonate adjuvant trials in a range of different patients have been released, two of these trials showed a survival benefit for the addition of a bisphosphonate to standard systemic therapy. ER-positive patients who are postmenopausal and have had no chemotherapy seemed to benefit the most.
Breast cancer tumors that have a loss of function in DNA-repair genes like BRCA1 and BRCA2 may be particularly sensitive to PARP inhibitors such as olaparib.
What are the latest advances in the treatment of triple-negative breast cancer? Are there new ways to molecularly characterize breast cancer tumors to identify specific mutation targets and increase the chance of response in this disease?
Rationale for prostate cancer screening continues to be debated as an update to a large European trial reconfirms a reduction in death rates from prostate cancer in men who are screened for the disease. The study, however, found no significant difference in overall mortality between the two arms of the trial.
Women who received estrogen while part of the Women's Health Initiative (WHI) trial had lower rates of invasive breast cancer compared to those who received placebo, and they were less likely to die of the disease compared to women who never took the hormone replacement therapy.
Two studies published today help clarify how to interpret CYP2D6 genetic testing and the results will likely affect the current trend of CYP2D6 genotyping prior to tamoxifen usage in early-stage ER-positive breast cancer patients.